Abstract
MYCN gene amplification and 1p deletion in neuroblastoma patients are associated with poor prognosis and commonly used for patient’s stratification into risk groups. MYCN copy number and 1p deletion status were analyzed with multiplex ligase-dependent probe amplification (MLPA), PCR and FISH. MYCN amplification was revealed in 21 patients (17.2%) simultaneously by MLPA and PCR. In 28 cases (23.0%) 2p gain was detected. 1p deletion was revealed in 28 patients (23.0%) while concordance between PCR and MLPA achieved 95.8%, PCR and FISH - 90.9%. Mean follow-up time achieved 42 months (ranged from 1 month to 13 years). Event-free survival and overall survival in MYCN-amplified patients as well as in patients with 1p deletion were significantly lower comparing with MYCN-negative patients or patients without 1p deletion.References
Друй А.Е., Цаур Г.А., Семенихина Е.Р. и др. Амплификации гена MYCN при нейробластоме. Методы выявления и прогностическое значение // Мед. генетика. - 2012. - № 9. - С. 25-30.
Ambros P.F., Ambros I.M., Kerbl R. et al. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas // Med Pediatr Oncol. - 2001. - Vol. 36. - P. 1-4.
Ambros I.M., Brunner B., Aigner G. et al. A Multilocus Technique for Risk evaluation of patients with neuroblastoma // Clin Cancer Res. - 2011. - Vol. 17. - P. 792-804.
Anderson J., Gibson S, Williamson D. et al. Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR / Pediatr Blood Cancer. - 2006. - Vol. 46. - P. 820-824.
Attiyeh E.F., London W.B., Moss Y.P. et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma // N Engl J Med. - 2005. - Vol. 353. - P. 2243-2253.
Brodeur G.M., Seeger R.C., Schwab M. et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage // Science. - 1984. - Vol. 224. - P. 1121-1124.
Evans A.E., Gerson J., Schnaufer L. Spontaneous regression of neuroblastoma // Natl Cancer Inst Monogr. - 1976. - Vol. 44. - P. 49-54.
George R.E., Kenyon R., McGuckin A.G. et al. Analysis of candidate gene co-amplification with MYCN in neuroblastoma // Eur J Cancer. - 1997. - Vol. 33. - P. 2037-2042.
Layfield L.J., Willmore-Payne C., Shimada H., Holden J.A. Assessment of NMYC amplification: a comparison of FISH., quantitative PCR monoplexing and traditional blotting methods used with formalin-fixed, paraffin-embedded neuroblastomas // Anal Quant Cytol Histol, 2005. - Vol. 27. - P. 5-14.
Look A.T., Hayes F.A., Shuster J.J. et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric oncology Group Study // J Clin Oncol. - 1991. - Vol. 9. - P. 581-591.
Manohar C.F., Salwen H.R., Brodeur G.M., Cohn S.L. Coamplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma // Genes Chromosomes Cancer. - 1995. - Vol. 14. - P. 196-203.
Maris J.M., White P.S., Beltinger C.P. et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma // Cancer Res. - 1995. - Vol. 55. - P. 4664-4669.
Ohtsu K., Hiyama E., Ichikawa T. et al. Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1 // Clin Cancer Res. - 1997. - Vol. 3. - P. 1221-1228.
Simon T., Spitz R., Faldum A. et al. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status // J Pediatr Hematol Oncol. - 2004. - Vol. 26. - P. 791-796.
Tonini G.P., Boni L., Pession A. et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children // J Clin Oncol. - 1997. - Vol. 15. - P. 85-93.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...